The present study characterized survival and immunologic response of bone marrow stromal cells (BMSCs) following transplantation into intact and stroke brains. In the first study, intrastriatal transplantation of BMSC (60,000 in 3 µl) or vehicle was performed in normal adult Sprague-Dawley male rats that subsequently received daily cyclosporin A (CsA, 10 mg/kg, IP in 3 ml) or vehicle (olive oil, similar volume) starting on day of surgery up to 3 days posttransplantation. Animals were euthanized at 3 or 30 days posttransplantation and brains were processed either for green fluorescent protein (GFP) microscopy or flow cytometry (FACS). Both GFP epifluorescence and FACS scanning revealed GFP+ BMSCs in both groups of transplanted rats with or without CsA, although significantly increased (1.6-to 3-fold more) survival of GFP+ BMSCs was observed in the immunosuppressed animals. Further histologic examination revealed widespread dispersal of BMSCs away from the graft core accompanied by many long outgrowth processes in non-CsA-transplanted animals, whereas a very dense graft core, with cells expressing only sporadic short outgrowth processes, was observed in CsA-transplanted animals. There were no detectable GFP+ BMSCs in nontransplanted rats that received CsA or vehicle. Immunologic response via FACS analysis revealed a decreased presence of cytotoxic cells, characterized by near complete absence of CD8+ cells, and lack of activation depicted by low CD69 expression in CsA-treated transplanted animals. In contrast, elevated levels of CD8+ cells and increased activation of CD69 expression were observed in transplanted animals that received vehicle alone. CD4+ helper cells were almost nondetectable in transplanted rats that received CsA, but also only minimally elevated in transplanted rats that received vehicle. Nontransplanted rats that received either CsA or vehicle displayed very minimal detectable levels of all three lymphocyte markers. In the second study, a new set of male Sprague-Dawley rats initially received bilateral stereotaxic intrastriatal transplantation of BMSCs and 3 days after were subjected to unilateral transient occlusion of middle cerebral artery. The animals were allowed to survive for 3 days after stroke without CsA immunosuppression. Epifluorescence microscopy revealed significantly higher (5-fold more) survival of transplanted GFP+ BMSCs in the stroke striatum compared with the intact striatum. The majority of the grafts remained within the original dorsal striatal transplant site, characterized by no obvious migration in intact striatum, but with long-distance migration along the ischemic penumbra in the stroke striatum. Moreover, FACS scanning analyses revealed low levels of immunologic response of grafted BMSCs in both stroke and intact striata. These results, taken together, suggest that xenotransplantation of mouse BMSCs into adult rats is feasible. Immunosuppression therapy can enhance xenograft survival and reduce graft-induced immunologic response; however, in the acute phase posttransplantation, BMSCs can survive in intact and stroke brain, and may even exhibit longdistance migration and increased outgrowth processes without immunosuppression.
INTRODUCTION
biological and molecular factors underlying stroke, there is no clinically proven means of either preventing the Stroke remains a leading cause of death in the US damage that results from a stroke or repairing the brain and around the world. Despite scientific advances on the following stroke. Indeed, only IV tissue plasminogen ac-tivator (tPA) treatment within 3 h of ischemic stroke (7,10,11). Of note, fetal VM cells survive better in the neurotoxin-induced denervated striatum than the normal, onset has shown efficacy in the laboratory and the clinic (29, 30, 52, 57, 72) . In the US alone approximately 750,000 intact striatum (36, 56) . These results suggest that a moderate degree of cell degeneration, but not severely dam-people suffer from strokes each year, resulting in an annual expenditure of $43 billion. In view of the limited aged (i.e., necrotic core) host, serves as a suitable transplant microenvironment. Differentiation of grafted cells therapeutic window of tPA to effectively mitigate the devastating effects of stroke, it is necessary to explore appears to be target specific, in that grafted NT2N cells mature into striatal-or cortical-like neurons when grafted novel stroke treatment strategies.
Cell replacement therapy has received considerable into the striatum and cortex, respectively (7,10,11). Similar target-specific differentiations have been demon-research attention as a potential treatment for stroke (4, 50, 53, 54, 63, 67) . Recent studies have demonstrated that strated in grafted olfactory ensheating cells (45) , bone marrow stromal cells (41), and stem/progenitor cells transplantation of fetal cells, immortalized cells, human neuroteratocarcinoma cells (NT2N), and stem or progen- (62, 84) . Finally, migration of grafted cells has been demonstrated to be directed by extrinsic, as well as in-itor cells derived from bone marrow or umbilical cord blood is effective in reducing histological and neurologi-trinsic, host-signaling mechanisms (28, 60, 83) . Collectively, these observations implicate the host microenvi-cal deficits in stroke animals (7, 10, 11, 25, (46) (47) (48) 58, 68) . Clinical trials of intracerebral transplantation of NT2N ronment as a critical factor in determining the eventual fate (e.g., survival, phenotype, and migratory potentials) cells have been initiated in stroke patients, and monitoring of the transplant recipients over a 5-year period has of grafted cells. Because NT2N cells are derived from cancer cells, indicated that this treatment is safe (42). However, the mechanisms underlying the therapeutic efficacy of neu-there is concern about the long-term phenotypic characteristics of these postmitotic cells following transplanta-ral transplantation in stroke remain to be determined. In addition, a major limiting factor for proceeding with tion into the stroke brain. Accordingly, stem/progenitor cells harvested from noncancerous bone marrow pose large-scale clinical trials of neural transplantation is the lack of an abundant, easily deliverable source of effica-as a much safer alternative graft source. Accumulating evidence has demonstrated behavioral recovery after cious cells. This logistical problem is compounded by the fact that even with an ample supply of donor cells, stroke in rats following bone marrow stromal cell (BMSC) transplantation (22, 46, 48, 49, 82) . However, there is scar-transplantation of these viable cells into the brain results in low graft survival possibly due to graft-versus-host city of data on the role of immunosuppression and host microenvironment on BMSC graft survival, which we immune response.
Immunosuppression has long been considered an ad-believe critically influence transplant-induced functional outcomes. Thus, the present study characterized graft junct therapy for neural transplantation (8, 18) . Although disagreement exists on the risk/benefit ratio of general survival and immunologic response following intracerebral xenotransplantation of mouse BMSCs in normal immunosuppression for transplant recipients (2, 17, 32) , most Parkinson's disease patients who have been trans-and stroke adult rats with or without immunosuppression. planted with ventral mesencephalic (VM) cells and exhibited significant clinical improvements had been MATERIALS AND METHODS subjected to short-term immunosuppression (19, 33, 43) .
Subjects Cyclosporin A (CsA) is the most common immunosuppressant and in recent years has been suggested as a All procedures adhered to NIH guidelines for using neuroprotective agent (4, 15, 20, 27, 44, 70) . Because of this animals in research. Male Sprague-Dawley rats (n = 58), new feature of CsA, which is also exerted by other imweighing 250-300 g, served as subjects. Food and water munosuppressants (i.e., tacrolimus) and their analogues were freely available to the animals in their house cage. (i.e., neuroimmunophilins), its use in neural transplanta-All surgical procedures were conducted under aseptic tion therapy indicates a multiple therapeutic action inconditions. cluding increased graft survival, as well as enhanced Donor Animals for Bone Marrow transplant-induced functional effects.
The host microenvironment has been shown to greatly BMSCs were harvested from adult male C57 BL/6-TgN (ACTbEGFP)1Osb mice (Jackson Labs). In this influence survival, phenotypic differentiation, and migration of transplanted cells. For example, we observed transgenic mouse line, an "enhanced" green fluorescent protein (GFP) cDNA under control of a chicken-actin no detectable surviving NT2N cell grafts when transplanted directly into the ischemic core, whereas we ob-promoter and cytomegalovirus enhancer makes all tissues, with the exception of erythrocytes and hair, appear tained about 15% graft survival of NT2N cells when transplant coordinates targeted the ischemic penumbra green under fluorescent light (38) . Bone marrow dissec-tion and BMSC isolation followed the procedures de-embolic technique that occludes the right MCA. Based on our studies and several others (6,12,14,23,29,31,32, scribed elsewhere (24, 46) . Briefly, tibias and femurs were dissected from 6-8-week-old GFP-positive mice under 58,73,74), a 1-h occlusion of the MCA results in maximal infarction. In addition, the length (15-17 mm) and aseptic conditions in a laminar flow hood. A 26-gauge sterile needle was used to flush bone marrow with size of the tip (24-26 gauge) of the embolus have been found to produce complete occlusion of MCA in ani-DMEM containing 20% fetal bovine serum (FBS). Marrow stromal cells (MSCs) were grown in culture in 35-mals weighing between 250 and 350 g. A Laser Doppler (Perimed PF5001 with probe 407-2; Sweden) was used mm plastic culture dishes using DMEM with 20% FBS and glutamine, penicillin/streptomycin, and pyruvate to verify successful MCA occlusion as we described previously (21, 25, 79) . A heating pad and a rectal ther-supplement. Total cells plated were 40 million in two 35-mm plastic dishes. Trypan blue exclusion revealed mometer allowed maintenance of body temperature at normal limits. 6.25% dead cell population. Twenty-four hours later, supernatant was discarded and cells were fed with DMEM GFP Epifluorescence Microscopy containing 20% FBS and supplements. Thereafter, cells were fed once a week until confluence. Cells from pas-Randomly selected animals (n = 3 per group for experiment 1 and n = 5 for experiment 2) were anesthe-sages 3 onwards were used for transplantation.
tized with a lethal dose (equithesin 500 mg/kg, IP), then Transplantation Surgery perfused with 150 ml saline and 150 ml 4% paraformaldehyde, and brains harvested and immersed in 25% su-All surgical procedures were conducted under aseptic conditions. Anesthetized animals were fixed in a Kopf crose for at least 24 h. Cryostat-sectioned brain tissues (20 µm thick) were examined via GFP epifluorescence. stereotaxic apparatus. Animals received unilateral (ipsilateral to the subsequent stroke; see below) stereotaxic Transplanted cells were detected directly with the use of a fluorescein isothiocyanate (FITC) filter set. To quan-transplantation. A small skull opening was made using a microsurgical drill and then a 28-gauge Hamilton sy-tify cell graft survival, 20 consecutive sectioned tissues were examined at 4× magnification and digitized using ringe was lowered into this opening. The transplant coordinates were adjusted to correspond to the striatal re-a PC-based Image Tools computer program. For estimation of surviving transplanted BMSCs, two observers gion: AP +2.0, ML ±2.0, DV −4.0 mm (61). This set of coordinates was based on our pilot studies using histo-blinded to the transplant condition performed the GFP cell counts on all 20 brain sections. logic assays demonstrating that this striatal region corresponds to the ischemic penumbra. The present cell dose Flow Cytometry of 60,000 BMSCs was selected based on our previous studies indicating this dose is within the effective cell Randomly selected animals (n = 3 per group for experiment 1 and n = 5 for experiment 2) were quickly dose range shown to produce behavioral recovery in stroke animals (7,10,11). The CsA dose and treatment decapitated and transplant site dissected out for FACS scanning analysis to detect GFP-tagged BMSCs. Pure schedule (10 mg/kg, IP, once a day) were also chosen based on our previous studies (7,10,11). For experiment GFP BMSCs (freshly harvested from culture preparations, which were the original source of donor cells used 1, randomly selected animals were assigned to one of the following treatment conditions (n = 12 per group): a) here, underwent the same treatment, i.e., trypsinization, as the BMSCs used for transplantation) were initially intrastriatal BMSC grafts + CsA; b) intrastriatal BMSC grafts + olive oil; c) intrastriatal saline infusion + CsA; assayed to reveal the localization of these cell population in the FACS scanner; this GFP-positive region was d) intrastriatal saline infusion + olive oil. Animals were euthanized at 3 or 30 days posttransplantation for histol-then "gated" and subsequently used as standard for detecting transplanted GFP BMSCs. Thereafter, FACS ogy (n = 3 per group) and flow cytometry (FACS, n = 3 per group) to characterize graft survival and immune scanning analysis was used to characterize the immunological response arising from such xenotransplantation. response. For experiment 2, a new set of animals (n = 10) underwent bilateral intrastriatal BMSC transplanta-Initially, tissue punches were made within the striatal sections corresponding to the transplant sites. Following tion without CsA immunosuppression. Three days following transplantation, animals were subjected to stroke mechanical dissociation and trypsinization, single-cell suspensions were obtained and sorted using antibodies surgery, then 3 days after were euthanized for similar histologic and immunologic assays.
directed towards subpopulations of T-cell lymphocytes, namely CD4 (helper) and CD8 (cytotoxic), and their ac-Stroke Surgery tivation marker CD69. To detect presence of T lymphocytes in the xenotransplants during FACS scanning, the Anesthetized (equithesin 300 mg/kg, IP) animals were subjected to the MCAo surgery using a well-established fluorochromes APC, PerCP, and PE were used for CD4, CD8, and CD69, respectively. In addition, all three lym-for days 3 and 30 graft maturation, respectively) or without CsA (2.2 ± 0.7% and 0.85 ± 0.4%), although more phocyte markers were double-labeled with CD5 (a 67-kDa glycoprotein on surface membrane of T cells; visu-surviving GFP fluorescent grafted cells were observed in the immunosuppressed animals (Figs. 1 and 2). ANOVA alized with FITC fluorochrome).
revealed treatment effects on graft survival, F(3, 20) =
Statistical Analysis
ANOVAs and t-tests were used to determine significant differences in graft survival and immune response levels (based on the three lymphocyte markers) between treatment groups. For experiment 1, a three-way ANOVA was used to analyze the following independent variables: graft (saline vs. BMSC), immunosuppression (oil vs. CsA), and time (3 vs. 30 days). Post hoc Bonferroni's t-tests were conducted thereafter for pairwise comparisons with statistical significance set at p < 0.05. For experiment 2, Student t-tests were used to compare the ipsilateral infarct striatum and the contralateral intact striatum from stroke animals, again with statistical significance set at p < 0.05. 87.82, p < 0.001, in that CsA-treated transplanted ani-ination revealed several outgrowth processes in BMSCs grafted in the stroke striatum, whereas only a few short mals had an additional 63.6% (1.6-fold) and 111.8% (2.1-fold) more cells, ts(5) = 19.22 and 35.91, p < 0.05, processes could be observed in BMSC grafts in the intact striatum. In addition, BMSC grafts in the stroke stri-than did vehicle-treated transplanted animals at 3 days and 30 days posttransplantation, respectively. On day 3 atum were dispersed significantly and a large number of grafted cells had migrated laterally and ventrally to-posttransplantation, the graft mass in CsA-treated transplanted animals was very dense and remained in the wards the ischemic striatal penumbra. In contrast, the graft mass of BMSCs transplanted in the intact striatum original transplant site with no obvious migration away from the graft core. In addition, the cells, both within remained compact and dense within the original transplant site and only a few cells had migrated away from and away from the graft core, did not exhibit any outgrowth processes. On day 30 posttransplantation, how-the graft core. ever, some grafted cells had dispersed away from the Flow Cytometry core and started to exhibit long outgrowth processes (Fig. 3) . In contrast, as early as day 3 posttransplanta-Experiment 1. In concert with histologic data above, tion, which was seen also at day 30 posttransplantation, flow cytometry revealed treatment effects on graft surthe graft core in vehicle-treated transplanted animals vival, F(3, 20) = 65.17, p < 0.001. FACS scanning analwas less dense and many cells had dispersed away from ysis revealed about a threefold increase in surviving the graft core and exhibited long outgrowth processes.
RESULTS
GFP fluorescent grafted cells in transplanted animals There were no observable GFP fluorescent cells in nonthat received CsA (10,140 ± 600 GFP+ BMSCs) comtransplanted rats that received CsA or vehicle.
pared with transplanted animals that received vehicle (3240 ± 250 GFP+ BMSCs) on both graft maturation pe-Experiment 2. Significantly increased graft survival of GFP+ BMSCs was observed in transplanted stroke riods, ts(5) = 39.23 and 46.14, ps < 0.05. There were no observable GFP fluorescent cells in nontransplanted rats striatum compared with the intact striatum [16.9 ± 3.2% vs. 5.4 ± 4.1%, respectively; t(5) = 20.12, p < 0.05] at 3 that received CsA or vehicle. Interestingly, ANOVA revealed treatment effects on immunologic response, spe-days poststroke (Figs. 4 and 5) . Further histologic exam- Figure 3 . Outgrowth processes of BMSC xenografts in intact striatum. At 3 days posttransplantation, BMSC grafts in CsA-treated transplanted animals displayed only short, nonelaborate outgrowth processes. In contrast, many BMSC grafts in vehicle-treated transplanted animals exhibited long outgrowth processes. However, when graft maturation was extended to 30 days, with CsA maintained only for the initial 3 days posttransplantation, BMSC grafts from both CsA-treated and vehicle-treated animals now showed many long outgrowth processes. Scale bar (for all): 0.1 mm. . BMSC xenograft survival in stroke striatum. GFP+ BMSC grafts were observed in both transplanted intact striatum (contralateral to stroke; A magnified in C) and the infarcted striatum (ipsilateral stroke; B magnified in D) at 3 days poststroke. A very dense mass of BMSCs was found in transplanted intact striatum, whereas a more dispersed appearance, with BMSCs lining the ischemic penumbra (dashed line), was observed in transplanted stroke striatum. In addition, a few BMSC grafts in the intact striatum displayed long outgrowth processes (E), whereas many grafted cells in stroke striatum exhibited long and elaborate processes (F). that received vehicle alone. CD4+ helper cells were almost nondetectable in transplanted rats that received CsA, but also only minimally elevated in transplanted rats that received vehicle; thus, there was no discernable difference ( ps > 0.05) in the number of CD4+ cells between controls and CsA-treated rats. Nontransplanted rats that received either CsA or vehicle displayed very minimal detectable levels of all three lymphocyte markers ( ps > 0.05). These data were consistent for both days 3 and 30 graft maturation periods. stroke striatum with intact striatum of stroke animals at 3 days poststroke, t(9) = 56.81, p < 0.05 (Fig. 7) . Furthermore, FACS revealed very low levels of immucifically on CD8 and CD69 expression, Fs (3, 20) = 51.89 nologic response, characterized by a near complete aband 47.55, ps < 0.01 (Fig. 6) . The increased graft sursence of CD4+, CD8+, and CD69+ BMSCs, which did vival in transplanted animals that received CsA conot differ between transplanted stroke and intact striata incided with decreased presence of cytotoxic cells, as (ps > 0.05). revealed by near complete absence of CD8+ cells, DISCUSSION ts(5) = 17.09 and 21.96, ps < 0.05, and lack of activation depicted by low CD69 expression, ts(5) = 20.10 and
The major findings of the present study are the fol-21.85, ps < 0.05, compared with transplanted animals lowing. 1) Short-term (over 3 days posttransplantation) immunosuppression in normal adult rats, which were intracerebrally transplanted with mouse BMSC xenografts, enhanced graft survival at 3 and 30 days posttransplantation, but delayed graft migration and outgrowth processes development. 2) Short-term immunosuppression reduced graft-derived immunologic response as revealed by absence or nondetectable levels of CD8 and CD69 expression. 3) Stroke created a more suitable host microenvironment as revealed by increased BMSC xenograft Figure 6 . BMSC graft-derived immune response. In the transplanted intact striata of animals that were not exposed to stroke, FACS detected minimal presence of cytotoxic cells, as revealed by near complete absence of CD8+ cells and CD69 expression (depicted as "Control"). In contrast, elevated levels of CD8+ cells and increased activation of CD69 expression were observed in transplanted animals that received vehicle alone. CD4+ helper cells were almost nondetectable in trans- Figure 7 . Comparison of BMSC xenograft survival across treatment groups. The order (from good to poor) survival of planted rats that received either CsA or vehicle. Similar low levels of immunologic response, characterized by a near com-GFP+ BMSC xenografts is as follows: stroke ipsilateral infarcted striatum > contralateral intact striatum from stroke ani-plete absence of CD4+, CD8+, and CD69+ BMSCs, were observed in both ipsilateral and contralated (to the stroke) striata mals > intact striatum from nonstroke (sham) animals. *p < 0.05. of transplanted animals exposed to stroke. survival, cell migration along the ischemic striatal pen-croenvironment has been shown to greatly influence survival, phenotypic differentiation, and migration of trans-umbra, and appearance of many long outgrowth processes.
planted cells (7,10,11, 28, 36, 45, 60, 62, 83, 84) . The long-term survival of BMSC xenografts in nor-Xenotransplantation presents as an alternative approach for cell replacement therapy, especially in view mal adult rats in the absence of chronic immunosuppression may be facilitated by novel features that BMSC of the lack of an abundant, easily deliverable source of efficacious cells. The present study supports the use of itself possesses. Recent studies have suggested that stem cells only minimally elicit immune response, and may BMSCs as a xenograft source. In the clinic, BMSCs may be harvested as an autograft, allograft, or xenograft (i.e., even secrete their own immunosuppressant factors following intracerebral transplantation (1, 49) . Because porcine bone marrow). However, successful survival of xenografts must be demonstrated to accept this trans-stem cells could be harvested from BMSCs, coupled with the present high survival of BMSC xenografts fol-plantation strategy. The use of CsA immunosuppression may alleviate the problem of xenograft rejection. How-lowing acute CsA treatment in normal animals and even without immunosuppression in stroke animals, it is ever, because deleterious side effects (e.g., hepatotoxicity, nephrotoxicity) are associated with general immuno-likely that BMSCs elicited minimal immune response and might have even released immunosuppressant fac-suppression, the risk/benefit ratio of pursuing such drug regimen must be considered. Of note, immunosuppres-tors (1, 49) and/or neurotrophic factors (23, 50) . Of note, immunosuppressant and neurotrophic factors have been sant-induced side effects are often observed with chronic treatment (5,9). Here we show that acute CsA treatment shown to protect against stroke (35, 74, 77, 78) . Our present observations of reduced graft-induced facilitated BMSC graft survival comparable with the reported 5%-8% graft survival seen in other cell types immunologic response following CsA treatment concur with published data demonstrating that CsA facilitates (e.g., fetal cells) with long-term immunosuppression (7, 13,34,43). Thus, while facilitating graft survival, short-transplant survival in other setups (8,19,26). As noted above, CsA may exert neuroprotection in addition to its term CsA may also circumvent the toxic side effects inherent with the drug. Although cell migration and out-primary immunosuppressive effects. Although the current view is that neuroprotection may be accomplished growth processes were delayed in CsA-treated normal animals, BMSC grafts eventually displayed similar pat-via a nonimmunosuppressive pathway (27, 37, 70) , the present data support the hypothesis that CsA neuropro-terns of migration and outgrowth projections seen in nonimmunosuppressed animals. Moreover, the present tection may involve immunosuppression. Furthermore, these results demonstrate the feasibility of FACS scan-study only compared early graft maturation at 3 days with long-term graft maturation at 30 days. It is possible ning analysis in characterizing the immunologic response accompanying CsA neuroprotection. Of note, a review that the onset of BMSC migration and outgrowth processes could have occurred at a much earlier time point of literature over the last decade revealed only two recent articles using FACS scanning analysis to detect the posttransplantation.
In recent years, immunosuppressants have been sug-immunologic response following neural transplantation. Brevig and colleagues (16) used FACS to measure mi-gested as very potent neuroprotective agents (15, 20, 27, 37, 44, 70) . Accumulating evidence has demonstrated that croglial content in the xenografts, while Armstrong and colleagues (1) performed FACS to reveal differences in immunosuppressants, such as CsA and tacrolimus and their analogues (i.e., neuroimmunophilins), exert graft MHCI and MHCII expression between transplanted neuronal precursor cells (MHCI+, MHCII−) and primary survival-enhancing effects, as well as improved transplant-induced functional effects. In vitro and in vivo cell preparations (MHCI+, MHCII+). Neither study investigated the effects of immunosuppressants on the studies in many animal models of neurological disorders, including Parkinson's disease and stroke, have transplants. Although FACS has been used to examine interactions between immunosuppressants and periph-shown that immunosuppressants increase outgrowth processes of host cells (27, 69, 71, 75) and grafted cells (20) . eral organ transplants, the present study is the first report of using such assay in studying CsA treatment following The present observations of increased graft survival with delayed development of outgrowth processes and migra-neural transplants. All the monoclonal antibodies used for characterizing the immunologic response in the pres-tion in immunosuppressed transplanted animals may indicate that CsA primarily exerts a proliferative effect, ent study were specific for mouse lymphocytes. Therefore, host rat lymphocytes remained undetectable by rather than facilitating differentiation and migration, in BMSC xenografts. In addition, CsA neuroprotective ef-these MoAbs. In the future, we plan to use MoAbs specific for rat and mouse T cells to discriminate the pro-fects may be influenced by the host microenvironment in that the present microenvironment utilized a "normal" portion of host-versus graft-derived T cells.
Another important finding in this study is the obser-striatum compared with the degenerating or damaged host tissues in the previous studies. Indeed, the host mi-vation of enhanced graft survival, cell migration along bradykinin receptor agonist, Cereport. Brain Res. Bull. 60: the ischemic striatal penumbra, and appearance of many ment is as follows: stroke ipsilateral infarcted striatum > Sanberg, P. R. Viability and survival of hNT neurons decontralateral to stroke intact striatum > nonstroke sham termine degree of functional recovery in grafted ischemic intact striatum (Fig. 7) . These results suggest that unilat- 
